Early research (Phase 1)Ended earlyNCT04800822What this trial is testingPF-07284892 in Participants With Advanced Solid TumorsWho this might be right forSolid Tumor Pfizer 53
Testing effectiveness (Phase 2)Looking for participantsNCT07237100What this trial is testingMirdametinib in Patients With Advanced NF1-mutant MelanomaWho this might be right forAdvanced Unresectable MelanomaMetastatic Melanoma Kevin Kim, MD 10
Testing effectiveness (Phase 2)Ended earlyNCT02315625What this trial is testingStudy of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive SurgeryWho this might be right forNeuroendocrine TumorsNeuroendocrine CarcinomaNeuroendocrine Neoplasms+2 more National Cancer Institute (NCI) 16
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439318What this trial is testingTesting Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)Who this might be right forAdvanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more National Cancer Institute (NCI) 50
Testing effectiveness (Phase 2)Ended earlyNCT04534283What this trial is testingA Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.Who this might be right forCancerCancer MetastaticBRAF V600E+4 more Anita Turk 16
Large-scale testing (Phase 3)Looking for participantsNCT04166409What this trial is testingThe Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade GliomaWho this might be right forLow Grade AstrocytomaLow Grade GliomaMetastatic Low Grade Astrocytoma+3 more National Cancer Institute (NCI) 170
Large-scale testing (Phase 3)Ended earlyNCT05130866What this trial is testingEfficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated MeningiomasWho this might be right forNeurofibromatosis Type 2 Recursion Pharmaceuticals Inc. 25
Early research (Phase 1)Looking for participantsNCT06961565What this trial is testingPAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform NeurofibromasWho this might be right forNF1 MutationNeurofibroma PlexiformNeurofibroma, Plexiform+2 more Pasithea Therapeutics Corp. 56
Testing effectiveness (Phase 2)Ended earlyNCT05554354What this trial is testingTesting the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)Who this might be right forAnatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Negative Breast CarcinomaMetastatic Hormone Receptor-Positive Breast Carcinoma National Cancer Institute (NCI) 1
Not applicableApproved For MarketingNCT03259633What this trial is testingAn Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1Who this might be right forNF type1 With Inoperable Plexiform Neurofibromas AstraZeneca
Not applicableNot Yet RecruitingNCT06834438What this trial is testingGene Therapy for Neurofibromatosis Type 2 (NF2) with ST002Who this might be right forNF2 Deficiency Cancer Institute and Hospital, Chinese Academy of Medical Sciences 9
Early research (Phase 1)Looking for participantsNCT03454035What this trial is testingUlixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid TumorsWho this might be right forTumor, SolidPancreatic CancerMelanoma UNC Lineberger Comprehensive Cancer Center 45
Testing effectiveness (Phase 2)Active Not RecruitingNCT03872427What this trial is testingTesting Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN StudyWho this might be right forAdvanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmNF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor+1 more National Cancer Institute (NCI) 54
Post-approval studies (Phase 4)Active Not RecruitingNCT03975829What this trial is testingPediatric Long-Term Follow-up and Rollover StudyWho this might be right forDiffuse AstrocytomaAnaplastic AstrocytomaAstrocytoma+20 more Novartis Pharmaceuticals 165
Testing effectiveness (Phase 2)Looking for participantsNCT05735717What this trial is testingMT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme MalignanciesWho this might be right forHematologic MalignancyAcute LeukemiaRemission+21 more Masonic Cancer Center, University of Minnesota 70
Early research (Phase 1)Temporarily pausedNCT03932253What this trial is testingMEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)Who this might be right forMelanoma Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 79
Not applicableUnknownNCT03757247What this trial is testingPrevalence of Constitutional Mismatch-repair Deficiency Among Suspected Neurofibromatosis Type 1/Legius Syndrome Children Without a Malignancy and Without a NF1 or SPRED1 MutationWho this might be right forNeurofibromatosis Type 1 Medical University Innsbruck 670
Early research (Phase 1)Looking for participantsNCT06299839What this trial is testingPAS-004 in Patients With Advanced Solid TumorsWho this might be right forRAS MutationNF1 MutationRAF Mutation+1 more Pasithea Therapeutics Corp. 48
Testing effectiveness (Phase 2)Study completedNCT02352844What this trial is testingEverolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 MutationsWho this might be right forSolid MalignancySolid Tumor Washington University School of Medicine 12
Testing effectiveness (Phase 2)Study completedNCT03989115What this trial is testingDose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCWho this might be right forSolid Tumor Revolution Medicines, Inc. 113